0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ViewRay
Its shares trade under the ticker VRAYQ. It has been listed since 4 November 2014. In the fiscal year to 31 December 2022, it reported revenue of $102.2m and a net loss of $107.3m. At that date it held total assets of $271.4m and shareholders' equity of $82.2m.
ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. The company is headquartered in Oakwood Village, Ohio. The company went IPO on 2014-11-04. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). The company provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. Its MRI system captures and displays live images in one plane, four times per second or in three planes, two times per second.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Nov 2014
- Employees
- 236
- Website
- viewray.com ↗
Leadership
Pay as last reported
- Mr. Daniel MooreIndependent Chairman of the Board$260,999
- Mr. Paul ZieglerPresident, Chief Executive Officer$1.7m
- Ms. Cassie MaharInterim Chief Financial Officer
- Mr. Adam PodbelskiSenior Vice President- Commercial Operations
- Dr. James DempseyChief Scientific Officer, since 2004$1.2m
- Dr. Caley CasteleinIndependent Director$212,166
- Ms. B. Kristine JohnsonIndependent Director$207,999
- Ms. Karen PrangeIndependent Director$200,999
- Mr. Brian RobertsIndependent Director$220,999
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 48
- Social
- 81
- Governance
- 34
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ViewRay Inc is a pioneering company in the field of image-guided radiation therapy, which allows for precise and targeted cancer treatments.
- The company's flagship product, the MRIdian system, offers real-time MRI imaging during radiation therapy, providing physicians with detailed visual information for accurate treatment delivery.
- ViewRay Inc has established a strong intellectual property portfolio, ensuring competitive advantage and legal protection for their innovative technology.
Weaknesses
- As a relatively young company, ViewRay Inc may face challenges in market penetration and brand recognition compared to more established competitors.
- The high cost of the MRIdian system may limit its adoption, especially in regions with budget constraints or insufficient insurance coverage.
- ViewRay Inc's technology heavily relies on MRI, which may pose limitations in terms of availability and compatibility with existing radiation therapy centers.
Opportunities
- The global demand for advanced cancer treatment options is increasing, providing opportunities for ViewRay Inc to expand its market share and revenue.
- Continuous technological advancements and improvements in MRI technology can enhance the capabilities and competitiveness of ViewRay Inc's products.
- Strategic partnerships with hospitals, research institutions, and healthcare providers can accelerate market penetration and facilitate product development.
Threats
- The medical device industry is highly regulated, and changes in regulations or compliance requirements may impact ViewRay Inc's operations and market access.
- Intense competition from well-established players in the radiation therapy market poses a threat to ViewRay Inc's market presence and growth potential.
- Economic downturns, healthcare budget constraints, or changes in reimbursement policies can affect the adoption and affordability of ViewRay Inc's technology.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.